STAAR Surgical (NASDAQ:STAA) Hits New 1-Year High on Strong Earnings

Shares of STAAR Surgical Company (NASDAQ:STAA) hit a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $35.87 and last traded at $31.7340, with a volume of 776926 shares changing hands. The stock had previously closed at $29.40.

The medical instruments supplier reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.07. The company had revenue of $93.52 million for the quarter, compared to analysts’ expectations of $78.72 million. STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.03%. STAAR Surgical’s revenue for the quarter was up 119.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.10) earnings per share.

More STAAR Surgical News

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR Surgical reported first-quarter results that beat Wall Street expectations, with EPS of $0.10 versus $0.03 expected and revenue of $93.52 million versus $78.72 million expected. The company also posted 119.6% year-over-year revenue growth, highlighting a sharp operational rebound.
• Positive Sentiment: Wedbush upgraded STAAR Surgical from neutral to outperform and set a $40 price target, implying meaningful upside from current levels. Wedbush upgrade on STAAR Surgical
• Positive Sentiment: The company said it delivered record first-quarter sales and profitability, reinforcing the view that momentum is improving after a weaker prior period. STAAR Surgical reports record Q1 sales and profitability
• Neutral Sentiment: Needham maintained a hold rating, saying trends look stable but visibility into the 2026 outlook remains limited. Needham maintains hold on STAAR Surgical
• Neutral Sentiment: Mizuho raised its price target from $22 to $27 but kept a neutral rating, suggesting the stock may have run ahead of that view. Mizuho raises price target on STAAR Surgical

Wall Street Analysts Forecast Growth

STAA has been the subject of a number of analyst reports. Piper Sandler restated a “neutral” rating and set a $33.00 price objective on shares of STAAR Surgical in a research report on Thursday. Mizuho upped their target price on STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a report on Thursday. Jefferies Financial Group lowered their price target on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating for the company in a report on Wednesday, January 28th. Weiss Ratings downgraded shares of STAAR Surgical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Finally, Morgan Stanley initiated coverage on shares of STAAR Surgical in a research note on Friday, January 16th. They issued an “underweight” rating and a $13.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $26.06.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, Director Broadwood Partners, L.P. bought 316,017 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director directly owned 16,123,842 shares of the company’s stock, valued at approximately $300,064,699.62. This trade represents a 2.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders bought 670,213 shares of company stock worth $12,266,249. 39.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On STAAR Surgical

A number of institutional investors and hedge funds have recently modified their holdings of STAA. Caitong International Asset Management Co. Ltd grew its position in shares of STAAR Surgical by 2,605.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 1,016 shares during the period. Ascentis Independent Advisors acquired a new position in shares of STAAR Surgical during the first quarter valued at about $77,000. Tower Research Capital LLC TRC raised its holdings in shares of STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 4,673 shares during the period. Russell Investments Group Ltd. boosted its position in shares of STAAR Surgical by 9,928.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock worth $121,000 after purchasing an additional 4,468 shares in the last quarter. Finally, Wolverine Asset Management LLC bought a new position in shares of STAAR Surgical during the 3rd quarter worth about $199,000. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Stock Performance

The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -19.67 and a beta of 1.20. The company has a 50 day moving average price of $22.22 and a 200 day moving average price of $22.54.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.